Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Company Data

Name Unicycive Therapeutics, Inc. - Common Stock

Company Unicycive Therapeutics, Inc.

Symbol UNCY

Website https://www.unicycive.com

Primary Exchange

NASDAQ

ISIN US90466Y1038

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Shalabh K. Gupta MPA

Market Capitalization 53 Mio

Country United States of America

Currency USD

Employees 0,0 T

Address 4300 El Camino Real, 94022 Los Altos

IPO Date 2021-07-12

Stock Splits

Date	Split
20.06.2025	1:10

Ticker Symbols

Name	Symbol
NASDAQ	UNCY

More Shares

Investors who hold Unicycive Therapeutics, Inc. - Common Stock also have the following shares in their portfolio:

LAND NRW SCH.R. VAR Bond

Thirumalai Chemicals Limited Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog